Power of Trial Might Be a Hurdle for Pfizer's Vyndaqel
By Mari Serebrov
Wednesday, May 23, 2012
Even though Pfizer Inc.'s Vyndaqel already is approved in Europe, getting U.S. approval for the orphan drug on the strength of a single pivotal trial is looking like it could be an uphill battle.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.